New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - capecitabine 150mg;  ;   - film coated tablet - 150 mg - active: capecitabine 150mg     excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 04f54305 - capecitabine tablets are indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine tablets in combination with docetaxel are indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - capecitabine 500mg;  ;   - film coated tablet - 500 mg - active: capecitabine 500mg     excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 04f54305 - capecitabine tablets are indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine tablets in combination with docetaxel are indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: croscarmellose sodium hypromellose opadry pink 03a540004 lactose magnesium stearate microcrystalline cellulose - capercit tablets are indicated for the adjuvant treatment of patients with dukes stage c and higher-risk stage b colon cancer, either as monotherapy or in combination with oxaloplatin

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: croscarmellose sodium hypromellose opadry pink 03a540003 lactose magnesium stearate microcrystalline cellulose - capercit tablets are indicated for the adjuvant treatment of patients with dukes stage c and higher-risk stage b colon cancer, either as monotherapy or in combination with oxaloplatin

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hypromellose; magnesium stearate; lactose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red - colon cancer ,capecitabine is indicated for the adjuvant treatment of patients with dukes stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated ,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red - colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated ,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.